MedTrace Logo

Calorie Restricted Dietary Intervention in Type 2 Diabetes Patients With Obesity for Remission

NCT07753447 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2026-08-07

No results posted yet for this study

Summary

This study aims to induce remission of type 2 diabetes through dietary intervention for weight reduction.

Conditions

  • Diabetes, Type 2
  • Obesity &Amp; Overweight

Interventions

DRUG

Contrave ER

Contrave is an extended-release combination of naltrexone and bupropion, approved for chronic weight management. It acts on the central nervous system to reduce appetite and control food cravings.

COMBINATION_PRODUCT

Low-calorie meal box

The meal boxes provided by CJ CheilJedang are nutritionally-balanced, low-calorie HMR products developed with reduced levels of sodium, sugar, and saturated fats.

Sponsors & Collaborators

  • HK inno.N Corporation

    collaborator INDUSTRY

  • Handok Inc.

    collaborator INDUSTRY

  • Kwang Dong Pharmaceutical co., ltd.

    collaborator INDUSTRY

  • Yeouido St. Mary's Hospital

    lead OTHER

Principal Investigators

  • Hyuk-Sang Kwon, MD, PhD · The Catholic University of Korea, College of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-01
Primary Completion
2026-01-27
Completion
2026-02-28

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07753447 on ClinicalTrials.gov